Skip to main content

Articles

Page 1 of 1

  1. Countries in sub-Saharan Africa with a high hepatitis B burden also have limited resources to identify underlying drivers of disease among key at-risk populations. To improve prioritization and strengthen prev...

    Authors: Joan Nankya-Mutyoba, Jim Aizire, Fredrick Makumbi, Lynn Atuyambe, Ponsiano Ocama and Gregory D. Kirk
    Citation: Hepatology, Medicine and Policy 2018 3:14
  2. Following publication of these three articles [1–3], it was flagged that the articles have an incorrect issue copyright year of 2017, because of an xml-related error.

    Authors:
    Citation: Hepatology, Medicine and Policy 2018 3:13

    The original article was published in Hepatology, Medicine and Policy 2016 2:6

    The original article was published in Hepatology, Medicine and Policy 2016 2:4

    The original article was published in Hepatology, Medicine and Policy 2016 2:5

  3. The Netherlands is striving to achieve national elimination of the hepatitis C virus (HCV) as one of the first countries worldwide. The favorable HCV epidemiology with both low prevalence and incidence, togeth...

    Authors: P. A. M. Kracht, J. E. Arends, K. J. van Erpecum, A. Urbanus, J. A. Willemse, A. I. M. Hoepelman and E. A. Croes
    Citation: Hepatology, Medicine and Policy 2018 3:12
  4. The metadata in the HTML format of the below original articles [1] were published with an incorrect cover date.

    Authors:
    Citation: Hepatology, Medicine and Policy 2018 3:11

    The original article was published in Hepatology, Medicine and Policy 2017 2:10

    The original article was published in Hepatology, Medicine and Policy 2017 2:9

    The original article was published in Hepatology, Medicine and Policy 2017 2:8

    The original article was published in Hepatology, Medicine and Policy 2017 2:7

  5. Hepatitis B and C represent an important co-infection for people living with HIV worldwide. Nepal wants to be part of the international mobilization for viral hepatitis elimination, and has pursued better unde...

    Authors: Marcelo Contardo Moscoso Naveira, Komal Badal, Jagadish Dhakal, Neichu Angami Mayer, Bina Pokharel and Ruben Frank Del Prado
    Citation: Hepatology, Medicine and Policy 2018 3:10
  6. Prevalence of Hepatitis C Virus (HCV) among people who inject drugs (PWID) is high. Risky injecting behaviours have been found to decrease in drug consumption rooms (DCRs) and supervised injecting facilities (...

    Authors: Vendula Belackova, Allison M. Salmon, Eberhard Schatz and Marianne Jauncey
    Citation: Hepatology, Medicine and Policy 2018 3:9
  7. Universal access to the hepatitis C direct acting antiviral (DAAs) regimens presents a unique opportunity to eliminate hepatitis C in Australia. Large numbers of Australians have already been cured using these...

    Authors: Jacqueline A. Richmond, Jeanne Ellard, Jack Wallace, Rachel Thorpe, Peter Higgs, Margaret Hellard and Alexander Thompson
    Citation: Hepatology, Medicine and Policy 2018 3:8
  8. After France removed hepatitis C treatment reimbursement restrictions on 25 May 2016, an expert report presented recommendations, which focused on vulnerable groups including people who inject drugs (PWID). Th...

    Authors: Jean-Michel Delile, Victor de Ledinghen, Marie Jauffret-Roustide, Perrine Roux, Brigitte Reiller, Juliette Foucher and Daniel Dhumeaux
    Citation: Hepatology, Medicine and Policy 2018 3:7
  9. In the United States, the highest burden of chronic hepatitis B (CHB) and CHB-related liver cancer is in the state of California, primarily in the San Francisco (SF) Bay and Los Angeles (LA) areas. The aim of ...

    Authors: Mehlika Toy, Bin Wei, Tejpal S. Virdi, An Le, Huy Trinh, Jiayi Li, Jian Zhang, Ann W. Hsing, Samuel K. So and Mindie H. Nguyen
    Citation: Hepatology, Medicine and Policy 2018 3:6
  10. Many persons infected with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) in the past are now lost to follow-up. The aim of the Northern Holland Hepatitis Retrieval Project (NHHRP) is to retrieve and re-e...

    Authors: N. Beekmans and M. Klemt-Kropp
    Citation: Hepatology, Medicine and Policy 2018 3:5
  11. Hepatic encephalopathy (HE) is one of the most important severe complications of liver cirrhosis. Thought to be caused by elevated blood levels of gut-derived neurotoxins (particularly ammonia) entering the br...

    Authors: Aleksander Krag, Marcus Schuchmann, Hanna Sodatonou, Jeff Pilot, James Whitehouse, Simone I. Strasser and Mark Hudson
    Citation: Hepatology, Medicine and Policy 2018 3:4
  12. WHO hepatitis B guidelines recommend testing all new HIV patients, treating them accordingly or providing immunization. At the Infectious Diseases Institute (IDI) following an audit done in 2012, only 46% pati...

    Authors: Musomba Rachel, Castelnuovo Barbara, Claire Murphy, Charlene Komujuni, Patience Nyakato, Ponsiano Ocama, Mohammed Lamorde, Philippa Easterbrook and Rosalind Parkes Ratanshi
    Citation: Hepatology, Medicine and Policy 2018 3:3
  13. The current model of care for the treatment of chronic hepatitis B (CHB) in Australia is through specialist Hepatology or Infectious Diseases clinics, and limited accredited primary care practices. Capacity is...

    Authors: Debra A. O’Leary, Eleanor Cropp, David Isaac, Paul V. Desmond, Sally Bell, Tin Nguyen, Darren Wong, Jessica Howell, Jacqui Richmond, Jenny O’Neill and Alexander J. Thompson
    Citation: Hepatology, Medicine and Policy 2018 3:1
  14. India is home to one in 14 of all chronic hepatitis B virus (HBV) cases, meaning that it is important to develop HBV interventions that are applicable in the Indian context. Vaccination is the foremost tool fo...

    Authors: Gourdas Choudhuri, Rajesh Ojha, T. S. Negi, Varun Gupta, Shipra Saxena, Arundhati Choudhuri, Sanjoy Pal, Jui Choudhuri and Alok Sangam
    Citation: Hepatology, Medicine and Policy 2017 2:10

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:11

  15. The 16 countries of the Eastern Europe and Central Asia (EECA) region are home to 6.6 million people in need of treatment for chronic hepatitis C virus (HCV) infection. Because of transformational change in HC...

    Authors: Ludmila Maistat, Natalija Kravchenko and Amulya Reddy
    Citation: Hepatology, Medicine and Policy 2017 2:9

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:11

  16. The International AIDS Society convened the 3rd International HIV/Viral Hepatitis Co-Infection Meeting on 17 July 2016 as part of the pre-conference program preceding the 21st International AIDS Conference hel...

    Authors: Tongai G. Maponga, Rachel Matteau Matsha, Sébastien Morin, Andrew Scheibe, Tracy Swan, Isabelle Andrieux-Meyer, C. Wendy Spearman, Marina B. Klein and Jürgen Kurt Rockstroh
    Citation: Hepatology, Medicine and Policy 2017 2:8

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:11

  17. Comprehensive information on the incidence and duration of hepatitis C virus (HCV) infection for people who inject drugs (PWID) in Ireland is not available. We created an incidence curve of injecting drug use ...

    Authors: Anne Marie Carew, Niamh Murphy, Jean Long, Kate Hunter, Suzi Lyons, Cathal Walsh and Lelia Thornton
    Citation: Hepatology, Medicine and Policy 2017 2:7

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:11

  18. Hepatitis B is preventable and hepatitis C is treatable even if still at a high cost; most people who are infected with hepatitis B or C virus have not been screened yet and are unaware of their infections; an...

    Authors: David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx, Daniel Shouval, John Ward and Pierre Van Damme
    Citation: Hepatology, Medicine and Policy 2016 1:16
  19. The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifest...

    Authors: Eberhard Schatz, Katrin Schiffer, Mags Maher, Magdalena Harris, Xavier Major Roca, Mojca Maticic and Astrid Leicht
    Citation: Hepatology, Medicine and Policy 2016 1:14
  20. The human immunodeficiency virus (HIV) epidemic in Russia, driven by injection drug use, has seen a steady rise in the past two decades. Hepatitis C virus (HCV) infection is highly prevalent in people who inje...

    Authors: Judith I. Tsui, Stephen C. Ko, Evgeny Krupitsky, Dmitry Lioznov, Christine E. Chaisson, Natalia Gnatienko and Jeffrey H. Samet
    Citation: Hepatology, Medicine and Policy 2016 1:13
  21. The inaugural World Hepatitis Summit was jointly convened by the World Health Organization (WHO) and the World Hepatitis Alliance and hosted by the Scottish Government and supported by Glasgow Caledonian Unive...

    Authors: Charles Gore, Stefan Wiktor, David Goldberg, Sharon Hutchinson, Jose Antonio Oñate Moreno and Raquel Peck
    Citation: Hepatology, Medicine and Policy 2016 1:12
  22. People who inject drugs (PWID) are disproportionately affected by both HIV and hepatitis C infection (HCV). Awareness of infection status is essential to ensure linkage to appropriate healthcare for those infe...

    Authors: Stine Nielsen, Martyna Gassowski, Benjamin Wenz, Norbert Bannert, Claus-Thomas Bock, Claudia Kücherer, R. Stefan Ross, Viviane Bremer, Ulrich Marcus and Ruth Zimmermann
    Citation: Hepatology, Medicine and Policy 2016 1:8
  23. HCV/HIV coinfection in people who inject drugs is a public health issue, which presents a variety of challenges to healthcare providers. The determinants of HCV/HIV coinfection in this population are nonethele...

    Authors: Anastasios Fotiou, Eleftheria Kanavou, Argyro Antaraki, Clive Richardson, Manina Terzidou and Anna Kokkevi
    Citation: Hepatology, Medicine and Policy 2016 1:9
  24. HIV co-infection exacerbates hepatitis C disease, increasing the risk of cirrhosis and hepatitis C-related mortality. Combination antiretroviral therapy (cART) is the current standard treatment for co-infected...

    Authors: Alexis Llewellyn, Mark Simmonds, Will L Irving, Ginny Brunton and Amanda J Sowden
    Citation: Hepatology, Medicine and Policy 2016 1:10
  25. India has a high burden of disease from hepatitis B virus (HBV), with 3.7 % point-prevalence, as well as from hepatitis C virus (HCV), with 1–1.5 % prevalence. Societal ignorance about HBV and HCV in India lim...

    Authors: Partha Sarathi Mukherjee, Eliza Dutta, Dipesh Kr. Das, Shatabdi Ghosh, Suvadip Neogi and Arka Sarkar
    Citation: Hepatology, Medicine and Policy 2016 2:6

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:13

  26. World Hepatitis Day 2016 marks one year since Hepatology, Medicine and Policy (HMAP) began accepting submissions. There have been many major developments in the fight against hepatitis B virus (HBV) and hepatitis...

    Authors: Jeffrey V. Lazarus, Kelly Safreed-Harmon and Mojca Maticic
    Citation: Hepatology, Medicine and Policy 2016 2:4

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:13

  27. Wilson’s disease is an inherited disorder in which defective biliary excretion of copper leads to its accumulation, particularly in the liver and brain. Mutations in the ATP7B gene on chromosome 13 cause Wilso...

    Authors: Francisco Hevia-Urrutia, Ileana Alvarado-Echeverría, Alfredo Sanabria-Castro, Marta Sánchez-Molina, Luis Meza-Sierra, Alexander Parajeles-Vindas, Oscar Méndez-Blanca, Álvaro Sánchez-Siles, Manuel Saborío-Rocafort, Marcela Barguil-Gallardo, Iliana Chavarría-Quirós and Cecilia Monge-Bonilla
    Citation: Hepatology, Medicine and Policy 2016 2:5

    The Correction to this article has been published in Hepatology, Medicine and Policy 2018 3:13

  28. Hepatitis B and C are major public health threats in the World Health Organization (WHO) European Region. Viral hepatitis surveillance shortcomings have resulted in many WHO Member States having insufficient d...

    Authors: Jeffrey V. Lazarus, Antons Mozalevskis, Kelly Safreed-Harmon and Irina Eramova
    Citation: Hepatology, Medicine and Policy 2016 1:3
  29. The Hepatitis C virus (HCV) is very common among people who inject drugs (PWID), yet PWID in India have suboptimal access to HCV testing and treatment. This study sought to identify HCV risk factors among male...

    Authors: Ruchi Sogarwal, Varada Madge, Pratyush Bishi, Apam Woleng and Rishi Garg
    Citation: Hepatology, Medicine and Policy 2016 1:1
  30. More than 17 million people in India are chronically infected with the hepatitis B virus (HBV). Approximately one million of the 26 million children born in India annually will develop chronic HBV infection in...

    Authors: Swati Jha, Divyesh Devaliya, Susan Bergson and Shripad Desai
    Citation: Hepatology, Medicine and Policy 2016 1:5
  31. Hepatitis B is an important disease of ethnic disparity which affects Asian Americans and other minority populations disproportionately. Despite the high prevalence of hepatitis B in Asian Americans, many of t...

    Authors: Chul S. Hyun, William R. Ventura, Soon S. Kim, Soyoung Yoon and Seulgi Lee
    Citation: Hepatology, Medicine and Policy 2016 1:6
  32. Hepatitis C virus (HCV) imposes a considerable disease burden in China, with at least 10 million people chronically infected. Little is known about the financial impact of the HCV epidemic, nor about the exten...

    Authors: Hai-yang Zhou, Shuang Liu, Su-jun Zheng, Xiao-xia Peng, Yu Chen, Carol Duan, Qing-fen Zheng, Zhao Wang and Zhong-ping Duan
    Citation: Hepatology, Medicine and Policy 2016 1:7
  33. This article describes hepatitis B-related knowledge, attitudes and practices after completion of the Gateway to Care campaign, a citywide public health education program that targeted city residents, health c...

    Authors: Chari Cohen, Alison A. Evans, Peixin Huang, W. Thomas London, Joan M. Block and Gang Chen
    Citation: Hepatology, Medicine and Policy 2016 1:4
  34. Data were obtained from the third National Survey of Knowledge, Attitudes and Practices of HIV and other Sexually Transmitted Infections (STI) (PCAP-2013) and used to describe the current state of viral hepati...

    Authors: Silvano Barbosa de Oliveira, Meritxell Sabidó, Ana Roberta Pati Pascom, Juliana Machado Gisiviez, Adele Schwartz Benzaken and Fábio Mesquita
    Citation: Hepatology, Medicine and Policy 2016 1:3
  35. New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitor...

    Authors: Stephen T. Barclay, Graham S. Cooke, Elizabeth Holtham, Aline Gauthier, Jeremie Schwarzbard, Petar Atanasov and William L. Irving
    Citation: Hepatology, Medicine and Policy 2016 1:2